Clone-Directed Therapy in Cold Agglutinin Disease

Prev
 1 / 12 
Next
Prev
 1 / 12 
Next

Learning objectives

After completing this quiz, the learner should be able to:

  • distinguish clone-directed therapy from complement inhibition by therapeutic goal, tempo of benefit, and clinical context
  • identify appropriate indications and limits of clone-directed therapy
  • select among rituximab-based regimens based on patient priorities, fitness, and risk
  • recognize common misapplications and timing errors in CAD management

The primary therapeutic goal of clone-directed therapy in primary CAD is to:

a
Rapidly block complement activation
This describes complement inhibition, which targets the effector pathway rather than disease origin.
b
Gradually suppress production of pathogenic IgM by the clonal B-cell population
Clone-directed therapy aims to suppress IgM production over time by targeting the responsible B-cell clone.
c
Eradicate the bone marrow clone completely
Complete eradication is not required and is not reliably achieved in CAD.
d
Stabilize patients during acute hemolytic crises
Clone-directed therapy is not effective for acute stabilization.

Which patient scenario is most appropriate for initiating clone-directed therapy alone?

a
Severe anemia with ongoing brisk complement-mediated hemolysis
Active, brisk hemolysis requires rapid effector-level control.
b
Hemodynamically unstable patient with transfusion-dependent hemolysis
Clone-directed therapy is too slow for acute instability.
c
Stable patient prioritizing finite therapy and long-term remission
Stable patients who value disease modification and accept delayed benefit are ideal candidates.
d
Patient requiring immediate improvement in hemoglobin
Immediate hemoglobin improvement is not a strength of clone-directed therapy.

Which statement best describes the relationship between clone size and hemolysis severity in CAD?

a
Larger clones always produce more severe hemolysis
Clinical severity does not reliably track with clone size.
b
Clone size directly predicts response to rituximab
Treatment response cannot be predicted by clone burden alone.
c
The relationship is variable and often weak
Hemolysis severity reflects IgM properties, complement activation, and host factors more than clone size.
d
Clone size determines urgency of treatment
Urgency is driven by clinical impact, not marrow metrics.

Why are myeloma-directed regimens generally not used in primary CAD?

a
They fail to suppress antibody production
Some myeloma therapies suppress antibody production, but they target the wrong biology.
b
The underlying disorder is typically an indolent B-cell lymphoproliferative disease, not a plasma cell neoplasm
Primary CAD arises from an indolent B-cell clone, not a plasma cell malignancy.
c
They require continuous administration
Continuous therapy is not the reason they are avoided.
d
They worsen complement activation
Complement activation is not directly worsened by these agents.

A 72-year-old patient with moderate CAD, recurrent infections, and a desire to minimize immunosuppression is considering clone-directed therapy. Which factor most favors rituximab monotherapy over rituximab–bendamustine?

a
Need for immediate hemolysis control
Neither regimen provides rapid control.
b
Higher likelihood of multi-year remission
Multi-year remissions are more likely with combination therapy.
c
Lower risk of prolonged immunosuppression
Rituximab monotherapy offers a more favorable toxicity profile in frail or infection-prone patients.
d
Greater depth of clone suppression
Deeper clone suppression is achieved with combination regimens.

Which represents a common misapplication of clone-directed therapy in CAD?

a
Initiating it only in patients with severe anemia
Clone-directed therapy is often appropriate in stable disease, not only severe anemia.
b
Delaying complement inhibition while awaiting clone suppression in unstable disease
Waiting for clone suppression during acute hemolysis risks clinical deterioration.
c
Weighing toxicity against comorbidity burden
This reflects appropriate clinical judgment.
d
Accepting delayed onset of benefit
Delayed benefit is an expected feature, not an error.

Sort each statement into the correct category

Suppresses pathogenic IgM production
Useful in acute exacerbations
Blocks complement-mediated hemolysis
Aims for long-term disease modification
Provides rapid anemia stabilization
Benefit typically emerges over weeks to months
Targets disease origin
Targets disease expression

Match each regimen to its typical role in CAD:

Rituximab monotherapy
Rituximab + bendamustine
Rituximab + fludarabine
Favored combination with multi-year remissions in fit patients
Modest responses, limited durability, lowest immunosuppression
Deeper remissions with substantial immunosuppression
Correct! Sorry, Incorrect.

Closing Note

Clone-directed therapy in CAD is not defined by who receives it, but by when and for what purpose. Errors of timing and therapeutic intent carry greater risk than conservative patient selection. Understanding the distinction between disease control and disease modification—and sequencing therapies accordingly—is central to safe, effective care.

Prev
 1 / 12 
Next